Omnibus IV Military Medical Research And Development (OMNIBUS IV)

The Defense Health Agency awarded Omnibus IV Military Medical Research and Development as a Master IDIQ on June 20, 2022, with ordering authority extending through June 19, 2032, providing 5 years 11 months of remaining opportunity. The vehicle succeeds Navy Medicine R&D Support Omnibus III and carries a shared ceiling of $10 billion across 57 distinct prime contractors.

Activity has declined sharply: 59 task orders were issued in 2023, 35 in 2024, 12 in 2025, and only 1 through March 2026. Combined task-order potential value stands at $619 million, of which $190.6 million (31 percent) has been obligated. The most recent delivery order was issued March 1, 2026.

Work spans military medical research, development, and support services. Recent task orders exemplify the scope: research support for infectious disease surveillance, blast-induced neurotrauma analysis, brain trauma neuroprotection, diarrheal disease antigen discovery and immunological research, medical countermeasures for wound infections, behavioral biology research, telemedicine and advanced technology development, implementation science, clinical investigations program support, hearing and vision center services, and clinical practice guideline development for military-relevant infectious diseases. Pricing is mixed—firm fixed price and cost plus fixed fee structures both appear.

Leidos, Inc. dominates by potential value with $159.2 million across 7 orders. Kapili Services, LLC ($65.7 million, 7 orders), Knowesis, Inc. ($63.2 million, 5 orders), Goldbelt C6, LLC ($60.3 million, 5 orders), and Culmen International, LLC ($43.4 million, 4 orders) follow. These five firms account for 63 percent of combined potential value. The Henry M. Jackson Foundation for the Advancement of Military Medicine holds 9 orders but only $24.5 million in combined potential value, and a long tail of 52 additional primes carry smaller awards.

Defense Health Agency dominates customer concentration, funding 93 of 107 task orders ($433.8 million combined potential value). The Department of the Navy Bureau of Medicine and Surgery placed 8 orders ($171.2 million), and DOD Uniformed Services University of the Health Sciences placed 6 orders ($14.1 million).

Set-aside activity is sparse: 76 percent of task orders carry no set-aside (81 orders), 16 percent are designated total small business (17 orders), and only 7 percent are competitive 8(a) (7 orders). A single woman-owned small business order and a single economically disadvantaged woman-owned small business order round out the mix.

Task-order values range widely—from nominal $2,500 administrative orders issued June 19, 2023, to $87.3 million potential value for deployment health research. Recent orders typically carry ceilings between $3 million and $37 million, with obligation periods ranging from roughly 18 months to 5 years.